Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
BeiGene
Biotech
BeiGene offers up $1.3B in biobucks for preclinical cancer drug
BeiGene is buying its way into a cancer niche targeted by Bayer, Blueprint Medicines, Incyte and Pfizer.
Nick Paul Taylor
Nov 21, 2023 7:13am
Novartis retreats from TIGIT, handing $300M drug back to BeiGene
Jul 11, 2023 9:20am
BeiGene bags option on DualityBio ADC in backloaded $1.3B deal
Jul 10, 2023 9:00am
Ex-J&J research chief lands at FogPharma—Chutes & Ladders
Mar 31, 2023 9:30am
BeiGene lets option on Leap’s immuno-oncology candidate lapse
Mar 17, 2023 8:50am
Agios replaces CEO after recent FDA nod—Chutes & Ladders
Jul 15, 2022 9:30am